news
Peptides face FDA scrutiny amid surging demand and supply
The FDA's Pharmacy Compounding Advisory Committee is considering tighter regulations on peptides, sparking debate between longevity clinics and scientists. This comes as the peptide market sees a massive boom, drawing comparisons to the early days of ride-sharing and short-term rentals. The committee's recommendations could shape access to these compounds.
The FDA's Pharmacy Compounding Advisory Committee is considering tighter regulations on peptides, sparking debate between longevity clinics and scientists. This comes as the peptide market sees a massive boom, drawing comparisons to the early days of ride-sharing and short-term rentals. The committee's recommendations could shape access to these compounds.
The architecture take
So, the peptide boom is going full Uber. Not in a 'cool disruptor' way, but in a 'regulators are about to get involved because things got out of hand' way. For years, peptides like BPC-157 or CJC-1295 have been available through compounding pharmacies, flying under the radar while helping with everything from gut repair to growth hormone release. But with everyone from biohackers to your aunt's golf buddy now dosing, the FDA is feeling the heat. They're weighing whether these should be compounded at all, which could yank them off the shelves for a lot of people. I've seen firsthand how these compounds can help recovery and tissue healing — but the wild west of sourcing and quality control needed a closer look. This isn't about safety in a vacuum; it's about whether the medical establishment can keep pace with consumer demand without stifling innovation.